Vaccine for protection against lawsonia intracellularis, mycoplasma hyopneumoniae and porcine circo virus

Abstract

The present invention pertains to a vaccine comprising in combination non-live antigens of Lawsonia intracellularis , of Mycoplasma hyopneumniae and Porcine circo virus, and a pharmaceutically acceptable carrier. The invention also pertains to a kit comprising a first container having contained therein non-live antigens of Lawsonia intracellularis , one or more other containers having contained therein Mycoplasma hyopneumoniae and Porcine circo virus antigens and instructions for mixing the antigens of Lawsonia intracellularis, Mycoplasma hyopneumoniae , and Porcine circo virus to formulate one combination vaccine suitable for systemic vaccination.

1 . A vaccine comprising in combination non-live antigens of  Lawsonia intracellularis, Mycoplasma hyopneumniae  and Porcine circo virus, and a carrier. 
     
     
         2 . The vaccine according to  claim 1 , characterised in that the vaccine is in a form suitable for systemic administration. 
     
     
         3 . The vaccine according to  claim 2 , characterised in that the non-live  Lawsonia intracellularis  antigens are obtained from a carbohydrate containing composition, the carbohydrate being also found in live  Lawsonia intracellularis  cells in association with the outer cell membrane of these cells. 
     
     
         4 . The vaccine according to  claim 3 , characterised in that the carbohydrate containing composition is material resulting from the killing of  Lawsonia intracellularis  bacteria. 
     
     
         5 . The vaccine according to  claim 4 , characterised in that the carbohydrate containing composition contains whole cells of killed  Lawsonia intracellularis  bacteria. 
     
     
         6 . The vaccine according to  claim 5 , characterised in that the vaccine comprises an oil in water adjuvant containing oil droplets of sub-micrometer size. 
     
     
         7 . The vaccine according to  claim 6 , characterised in that the adjuvant comprises droplets of biodegradable oil and droplets of mineral oil, the droplets of biodegradable oil having an average size that differs from the average size of the droplets of mineral oil. 
     
     
         8 . A kit comprising a first container having contained therein non-live antigens of  Lawsonia intracellularis , one or more other containers having contained therein  Mycoplasma hyopneumoniae  and Porcine circo virus antigens and instructions for mixing the antigens of  Lawsonia intracellularis, Mycoplasma hyopneumoniae , and Porcine circo virus to formulate one combination vaccine suitable for systemic vaccination. 
     
     
         9 . The kit according to  claim 8 , wherein the  Mycoplasma hyopneumoniae  and Porcine circo virus antigens are contained in one container, formulated in an oil in water adjuvant. 
     
     
         10 . The vaccine according to  claim 1 , characterised in that the non-live  Lawsonia intracellularis  antigens are obtained from a carbohydrate containing composition, the carbohydrate being also found in live  Lawsonia intracellularis  cells in association with the outer cell membrane of these cells. 
     
     
         11 . The vaccine according to  claim 10 , characterised in that the carbohydrate containing composition is material resulting from the killing of  Lawsonia intracellularis  bacteria. 
     
     
         12 . The vaccine according to  claim 11 , characterised in that the carbohydrate containing composition contains whole cells of killed  Lawsonia intracellularis  bacteria. 
     
     
         13 . The vaccine according to  claim 12 , characterised in that the vaccine comprises an oil in water adjuvant containing oil droplets of sub-micrometer size. 
     
     
         14 . The vaccine according to  claim 13 , characterised in that the adjuvant comprises droplets of biodegradable oil and droplets of mineral oil, the droplets of biodegradable oil having an average size that differs from the average size of the droplets of mineral oil. 
     
     
         15 . The vaccine according to  claim 3 , characterised in that the vaccine comprises an oil in water adjuvant containing oil droplets of sub-micrometer size. 
     
     
         16 . The vaccine according to  claim 15 , characterised in that the adjuvant comprises droplets of biodegradable oil and droplets of mineral oil, the droplets of biodegradable oil having an average size that differs from the average size of the droplets of mineral oil. 
     
     
         17 . The vaccine according to  claim 2 , characterised in that the vaccine comprises an oil in water adjuvant containing oil droplets of sub-micrometer size. 
     
     
         18 . The vaccine according to  claim 17 , characterised in that the adjuvant comprises droplets of biodegradable oil and droplets of mineral oil, the droplets of biodegradable oil having an average size that differs from the average size of the droplets of mineral oil.